Follow the Money
The global urology devices market was valued at approximately $34.1 billion in 2023 and is projected to grow to $48.6 billion by 2028, with a compound annual growth rate of 7.3%.
That's a lot of money flowing through a system designed to manage urological conditions. But how much is invested in preventing them and offering curative treatment?
The Disease Management vs. Prevention Paradox
Consider the economics:
Disease Management generates revenue through:
- Diagnostic procedures
- Prescription medications
- Surgical interventions
- Medical devices
- Follow-up care
- Complication management
- Repeat procedures
Prevention generates revenue through:
- ...educational materials?
- ...hygiene products?
The financial incentives are clear!
What Patients Face
The average BPH patient journey follows a predictable progression: years of symptoms before seeking care → multiple medications with varying effectiveness → side effects requiring additional medical management → potential surgical intervention (17% complication rate for TURP) → likely further medical management (5–7% within 1–5 years) → ongoing monitoring and follow-up. Each step generates healthcare revenue.
The Prevention Alternative
What if patients could:
- Maintain urogenital health proactively
- Prevent the inflammation cascade before it starts
- Avoid the need for expensive interventions
- Preserve quality of life throughout aging
This approach would be better for patients—but what would it mean for a $48.6 billion industry?
The Parallels in History
We've seen this pattern before:
- Tobacco industry fought evidence linking smoking to cancer
- Sugar industry downplayed connections to diabetes and obesity
- Pharmaceutical companies have faced criticism for prioritizing symptom management over curative treatment
Is it possible that prevention for urological conditions faces similar headwinds?
What You Can Do
Regardless of industry incentives, individuals can:
- Educate themselves about urogenital health
- Ask questions about prevention strategies
- Demand better from the healthcare system
- Advocate for prevention-focused research
The Bottom Line
When there's $48.6 billion at stake, it's worth asking: whose interests does the current system serve?
Prevention may be cheaper than disease management—but that's precisely the problem for an industry built on managing disease.